Morgan Stanley initiates ADARx stock with overweight rating
Morgan Stanley initiated coverage on ADARx Pharmaceuticals (NASDAQ:ADRX) with an overweight rating and a $32.00 price target, suggesting 81% upside. The company has a market cap of $1.98 billion and a pipeline of liver-targeted treatments. UBS and TD Cowen also initiated coverage with Buy ratings and higher price targets. ADARx recently completed an IPO, raising $446.3 million.
How this was made
The 30-second read
Why it matters
Analyst initiations provide a fresh catalyst that could drive short‑term price appreciation.
Market read
First analyst coverage for a newly listed biotech, offering a potential trade trigger.
What to watch
Upcoming Phase 3 data for onvuzosiran and Phase 2 readouts in 2027 could materially affect valuation.
Background
ADARx Pharmaceuticals recently completed its IPO at $17 per share, raising roughly $446 million.
Ticker impact
Morgan Stanley initiated coverage on ADARx Pharmaceuticals with an overweight rating and a $32 price target, marking the first analyst upgrade for the newly listed biotech.
likely upward pressure as the market prices in the new rating and target price.
The coverage is the first such upgrade post‑IPO, providing fresh catalyst for traders.
Market effects
Highlights growing investor interest in late‑stage RNA therapeutics, potentially lifting peer biotech stocks.
US biotech sector may see modest gains as a new entrant receives strong analyst support.
Limited to biotech investors; no broader macro impact.
Counterpoint
The rating may be premature given ADARx's early-stage pipeline and reliance on future trial data.
Key entities
- AnalystMorgan Stanley
Initiated coverage with overweight rating and $32 target.
- AnalystUBS
Also initiated coverage with a $35 target.
